KR20190044079A - 글루카곤 수용체 신호전달을 간섭함에 의한 중증 인슐린 저항성의 치료 방법 - Google Patents

글루카곤 수용체 신호전달을 간섭함에 의한 중증 인슐린 저항성의 치료 방법 Download PDF

Info

Publication number
KR20190044079A
KR20190044079A KR1020197008021A KR20197008021A KR20190044079A KR 20190044079 A KR20190044079 A KR 20190044079A KR 1020197008021 A KR1020197008021 A KR 1020197008021A KR 20197008021 A KR20197008021 A KR 20197008021A KR 20190044079 A KR20190044079 A KR 20190044079A
Authority
KR
South Korea
Prior art keywords
ser
gly
group
leu
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197008021A
Other languages
English (en)
Korean (ko)
Inventor
제스퍼 그로마다
하루카 오카모토
스티븐 제스퍼스
조이스 하프
Original Assignee
리제너론 파마슈티칼스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59799505&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20190044079(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 리제너론 파마슈티칼스 인코포레이티드 filed Critical 리제너론 파마슈티칼스 인코포레이티드
Priority to KR1020237014250A priority Critical patent/KR102708864B1/ko
Publication of KR20190044079A publication Critical patent/KR20190044079A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020197008021A 2016-08-30 2017-08-29 글루카곤 수용체 신호전달을 간섭함에 의한 중증 인슐린 저항성의 치료 방법 Ceased KR20190044079A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237014250A KR102708864B1 (ko) 2016-08-30 2017-08-29 글루카곤 수용체 신호전달을 간섭함에 의한 중증 인슐린 저항성의 치료 방법

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662381263P 2016-08-30 2016-08-30
US62/381,263 2016-08-30
US201662411032P 2016-10-21 2016-10-21
US62/411,032 2016-10-21
PCT/US2017/049137 WO2018044903A1 (en) 2016-08-30 2017-08-29 Methods of treating severe insulin resistance by interfering with glucagon receptor signaling

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237014250A Division KR102708864B1 (ko) 2016-08-30 2017-08-29 글루카곤 수용체 신호전달을 간섭함에 의한 중증 인슐린 저항성의 치료 방법

Publications (1)

Publication Number Publication Date
KR20190044079A true KR20190044079A (ko) 2019-04-29

Family

ID=59799505

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020197008021A Ceased KR20190044079A (ko) 2016-08-30 2017-08-29 글루카곤 수용체 신호전달을 간섭함에 의한 중증 인슐린 저항성의 치료 방법
KR1020247021936A Ceased KR20240110661A (ko) 2016-08-30 2017-08-29 글루카곤 수용체 신호전달을 간섭함에 의한 중증 인슐린 저항성의 치료 방법
KR1020237014250A Active KR102708864B1 (ko) 2016-08-30 2017-08-29 글루카곤 수용체 신호전달을 간섭함에 의한 중증 인슐린 저항성의 치료 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020247021936A Ceased KR20240110661A (ko) 2016-08-30 2017-08-29 글루카곤 수용체 신호전달을 간섭함에 의한 중증 인슐린 저항성의 치료 방법
KR1020237014250A Active KR102708864B1 (ko) 2016-08-30 2017-08-29 글루카곤 수용체 신호전달을 간섭함에 의한 중증 인슐린 저항성의 치료 방법

Country Status (13)

Country Link
US (3) US10995146B2 (https=)
EP (1) EP3506940A1 (https=)
JP (3) JP7173962B2 (https=)
KR (3) KR20190044079A (https=)
CN (2) CN118236497A (https=)
AU (2) AU2017321423C1 (https=)
CA (1) CA3034777A1 (https=)
IL (2) IL322691A (https=)
MA (1) MA46089A (https=)
MX (2) MX385598B (https=)
NZ (1) NZ750953A (https=)
SG (2) SG10201913074WA (https=)
WO (1) WO2018044903A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12398202B2 (en) 2019-09-04 2025-08-26 Apharma Use of ITIH1 as biomarker for detection of insulin resistance in diseases accompanied by impaired glucose tolerance

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA46089A (fr) 2016-08-30 2019-07-10 Regeneron Pharma Procédés de traitement de la résistance à l'insuline grave par interférence avec la signalisation du récepteur du glucagon
CN110357959B (zh) 2018-04-10 2023-02-28 鸿运华宁（杭州）生物医药有限公司 Gcgr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
JP2022523301A (ja) * 2019-01-23 2022-04-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッド アンジオポエチン様７（ａｎｇｐｔｌ７）阻害剤による眼疾患の治療
US20220288169A1 (en) * 2019-05-24 2022-09-15 The Board of Supervisors of Louisiana State University and Agriculyural and Mechanical College Compositions and methods for the treatment and prevention of hypoglycemic complications
CN113481290B (zh) * 2021-06-30 2022-08-23 华南农业大学 一种klf4基因在制备检测和/或减少母鼠不良妊娠结局的产品中的应用
CN114342875A (zh) * 2022-01-12 2022-04-15 吉林大学 一种新型妊娠糖尿病动物模型的建立方法
EP4708502A1 (en) 2023-08-21 2026-03-11 LG Energy Solution, Ltd. Cell assembly, battery module including same, and method for manufacturing cell assembly

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5836308B2 (ja) 1977-02-10 1983-08-08 大塚製薬株式会社 抗体の製造方法
US4206199A (en) 1977-07-22 1980-06-03 Takeda Chemical Industries, Ltd. Novel glucagon fragment and its derivatives
JPS56163456A (en) 1980-05-21 1981-12-16 Otsuka Pharmaceut Co Ltd Preparation of antigen
US4423034A (en) 1980-10-16 1983-12-27 Toyo Jozo Kabushiki Kaisha Process for the preparation of antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0658200B1 (en) 1992-08-28 2004-12-22 Novo Nordisk A/S Glucagon receptors
JP2729159B2 (ja) 1994-10-31 1998-03-18 日清製粉株式会社 ヒトグリセンチンのモノクローナル抗体、この抗体を産生するハイブリドーマおよびそれを用いるヒトグリセンチンの定量法
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
CA2547785A1 (en) 2003-12-19 2005-07-21 Merck & Co., Inc. Cyclic guanidines, compositions containing such compounds and methods of use
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
DE602005006806D1 (de) 2004-06-04 2008-06-26 Merck & Co Inc Pyrazolderivate, zusammensetzungen, die solche verbindungen enthalten, und anwendungsverfahren
DE102004028862A1 (de) 2004-06-15 2005-12-29 Merck Patent Gmbh 3-Aminoindazole
AU2005272043B2 (en) 2004-07-07 2010-07-29 Merck Sharp & Dohme Corp. Pyrazole amide derivatives, compositions containing such compounds and methods of use
US7625938B2 (en) 2004-07-22 2009-12-01 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
SI1856090T1 (sl) 2005-02-11 2010-02-26 Lilly Co Eli Substituirani derivati tiofena kot antagonisti glukagonskega receptorja, priprava in terapevtske uporabe
US8318760B2 (en) 2005-03-21 2012-11-27 Merck Sharp & Dohme Corp. Substituted aryl and heteroaryl derivatives, compositions containing such compounds and methods of use
US7803951B2 (en) 2005-03-30 2010-09-28 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
AR056574A1 (es) 2005-10-19 2007-10-10 Merck & Co Inc Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
CA2649751A1 (en) 2006-04-20 2007-11-01 Amgen Inc. Glp-1 compound/glucagon antibody compositions
CL2007002668A1 (es) 2006-09-20 2008-05-09 Amgen Inc Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2.
TW200821284A (en) 2006-10-03 2008-05-16 Merck & Co Inc Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
KR20190126460A (ko) 2007-02-09 2019-11-11 메타베이시스 테라퓨틱스, 인크. 글루카곤 수용체의 길항제
CL2009000586A1 (es) 2008-03-27 2010-06-04 Lilly Co Eli Fragmento fab o anticuerpo monoclonal humanizado que lo comprende que se une a receptor de glucagon humano/glucr, de rata, de raton, y mono cinomolgus; vector que comprende polinuccleotido codificante; celula huesped que lo comprende; composicion farmaceutica; uso para tratar diabetes tipo 1 o 2, o para la perdida de peso
EP2291358B1 (en) 2008-05-16 2018-03-28 Merck Sharp & Dohme Corp. Glucagon receptor antagonists, compositions, and methods for their use
EP2346830B1 (en) 2008-09-15 2015-05-13 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2010071750A1 (en) 2008-12-19 2010-06-24 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds
US20110281795A1 (en) 2009-01-28 2011-11-17 Songnian Lin Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US8324384B2 (en) 2009-02-12 2012-12-04 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US8809579B2 (en) 2009-02-13 2014-08-19 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US8318667B2 (en) 2009-02-25 2012-11-27 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
JP2012188352A (ja) 2009-07-13 2012-10-04 Dainippon Sumitomo Pharma Co Ltd ３−（４−置換アルキル−フェニル）−２−フランカルボン酸誘導体およびその薬学的に許容される塩
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
ES2796556T3 (es) 2011-09-20 2020-11-27 Ionis Pharmaceuticals Inc Modulación antisentido de la expresión de GCGR
US9453073B2 (en) 2011-12-02 2016-09-27 Eli Lilly And Company Anti-glucagon antibodies and uses thereof
MX2015015339A (es) 2013-05-07 2016-07-15 Rinat Neuroscience Corp Anticuerpos de receptor anti-glucagon y metodos de uso de los mismos.
KR20170062466A (ko) 2014-09-16 2017-06-07 리제너론 파마슈티칼스 인코포레이티드 항-글루카곤 항체 및 그것의 사용
MA46089A (fr) 2016-08-30 2019-07-10 Regeneron Pharma Procédés de traitement de la résistance à l'insuline grave par interférence avec la signalisation du récepteur du glucagon

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12398202B2 (en) 2019-09-04 2025-08-26 Apharma Use of ITIH1 as biomarker for detection of insulin resistance in diseases accompanied by impaired glucose tolerance

Also Published As

Publication number Publication date
JP2022140605A (ja) 2022-09-26
NZ750953A (en) 2026-02-27
WO2018044903A1 (en) 2018-03-08
US20210221896A1 (en) 2021-07-22
EP3506940A1 (en) 2019-07-10
IL264879B1 (en) 2026-03-01
US20190218301A1 (en) 2019-07-18
RU2019107807A (ru) 2020-10-01
JP2019528306A (ja) 2019-10-10
JP7633213B2 (ja) 2025-02-19
KR20230062673A (ko) 2023-05-09
CN118236497A (zh) 2024-06-25
KR20240110661A (ko) 2024-07-15
RU2019107807A3 (https=) 2021-05-18
MX2021006457A (es) 2021-07-02
AU2024278594A1 (en) 2025-01-30
JP2024178249A (ja) 2024-12-24
MX2019002437A (es) 2019-10-09
JP7173962B2 (ja) 2022-11-16
SG10201913074WA (en) 2020-03-30
KR102708864B1 (ko) 2024-09-25
MX385598B (es) 2025-03-18
IL264879A (https=) 2019-04-30
AU2017321423A1 (en) 2019-03-14
US20230416384A1 (en) 2023-12-28
CN109922831A (zh) 2019-06-21
IL322691A (en) 2025-10-01
SG11201901355SA (en) 2019-03-28
US11708416B2 (en) 2023-07-25
MA46089A (fr) 2019-07-10
AU2017321423B2 (en) 2024-09-26
CA3034777A1 (en) 2018-03-08
AU2017321423C1 (en) 2025-01-30
US10995146B2 (en) 2021-05-04

Similar Documents

Publication Publication Date Title
KR102708864B1 (ko) 글루카곤 수용체 신호전달을 간섭함에 의한 중증 인슐린 저항성의 치료 방법
AU2018253544B2 (en) Methods for treating or preventing asthma by administering an IL-4R antagonist
KR101781786B1 (ko) 사람 안지오포이에틴-2에 대한 고 친화성 사람 항체
KR101952786B1 (ko) 글루카곤 수용체에 대한 인간 항체
KR101842570B1 (ko) 사람 안지오포이에틴-유사 단백질 4에 대한 사람 항체
KR102111941B1 (ko) 항-ａｓｉｃ1 항체 및 그 용도
KR20160030581A (ko) 항-액티빈 a 항체 및 그의 용도
CN111789944A (zh) 用前蛋白转化酶枯草溶菌素-9(PCSK9)抑制剂降低脂蛋白(a)水平的方法
KR20170062466A (ko) 항-글루카곤 항체 및 그것의 사용
KR20120059611A (ko) 인간 프로테아제-활성화된 수용체-2에 대한 고친화도 인간 항체들
US20250101119A1 (en) Methods of treating urea cycle disorders by interfering with glucagon receptor signaling
RU2772508C2 (ru) Способы лечения тяжелой инсулинорезистентности путем прерывания передачи сигнала глюкагонового рецептора
HK40114568A (zh) 通过干扰胰高血糖素受体的信号传导治疗重度胰岛素抵抗的方法
HK1166806B (en) High affinity human antibodies to human angiopoietin-2

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190320

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200819

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220107

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220718

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220107

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20220718

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20220307

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20200819

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20221125

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20221017

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20220718

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20220307

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20220107

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20200819

X601 Decision of rejection after re-examination